6-Hydroxydopamine hydrobromide

Pricing Availability   Qty
Cat.No. 2547 - 6-Hydroxydopamine hydrobromide | C8H11NO3.HBr | CAS No. 636-00-0
Description: Selective catecholaminergic neurotoxin
Alternative Names: 6-OHDA
Chemical Name: 5-(2-Aminoethyl)-1,2,4-benzenetriol hydrobromide
Datasheet
Citations (11)
Reviews (2)
Literature (3)

Biological Activity

Selective catecholaminergic neurotoxin. Depletes brain catecholamine levels via uptake and accumulation by a transport mechanism specific to these neurons. Causes almost complete destruction of nigral dopaminergic neurons and their striatal terminals when injected into the substantia nigra of rats, producing an animal model of Parkinson's disease.

Technical Data

M. Wt 250.09
Formula C8H11NO3.HBr
Storage Desiccate at -20°C
CAS Number 636-00-0
PubChem ID 176170
InChI Key MLACDGUOKDOLGC-UHFFFAOYSA-N
Smiles NCCC1=CC(O)=C(O)C=C1O.Br

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 20.56 100
DMSO 20.56 100

Preparing Stock Solutions

The following data is based on the product molecular weight 250.09. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 4 mL 19.99 mL 39.99 mL
5 mM 0.8 mL 4 mL 8 mL
10 mM 0.4 mL 2 mL 4 mL
50 mM 0.08 mL 0.4 mL 0.8 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Breese and Traylor (1970) Effect of 6-hydroxyDA on brain NE and DA: evidence for selective degeneration of catecholamine neurons. J.Pharmacol.Exp.Ther. 174 413 PMID: 5456173

Soto-Otero et al (2000) Autoxidation and neurotoxicity of 6-hydroxyDA in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J.Neurochem. 74 1605 PMID: 10737618

Fujita et al (2006) Cell-permeable cAMP analog suppresses 6-hydroxyDA-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 1113 10 PMID: 16945353


If you know of a relevant reference for 6-Hydroxydopamine hydrobromide, please let us know.

Keywords: 6-Hydroxydopamine hydrobromide, 6-Hydroxydopamine hydrobromide supplier, Selective, catecholaminergic, neurotoxin, Dopamine, Receptors, adrenoceptors, adrenergic, dopaminergic, neurotoxins, parkinson's, parkinsons, 6-OHDA, Dopaminergic-Related, Adrenergic, Related, Compounds, 2547, Tocris Bioscience

11 Citations for 6-Hydroxydopamine hydrobromide

Citations are publications that use Tocris products. Selected citations for 6-Hydroxydopamine hydrobromide include:

Fan (2018) External light activates hair follicle stem cells through eyes via an ipRGC-SCN-sympathetic neural pathway. Proc Natl Acad Sci U S A. 115 E6880 PMID: 29959210

Sérriàre et al (2015) Assessment of the Protection of DArgic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model. PLoS One 2 61 PMID: 26389120

Ray et al (2014) Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a C. elegans Parkinson's model. Cell Death Dis 5 e984 PMID: 24407237

Fouillet et al (2012) ER stress inhibits neuronal death by promoting autophagy. Front Med (Lausanne) 8 915 PMID: 22660271


Do you know of a great paper that uses 6-Hydroxydopamine hydrobromide from Tocris? Please let us know.

Reviews for 6-Hydroxydopamine hydrobromide

Average Rating: 4.5 (Based on 2 Reviews.)

5 Star
50%
4 Star
50%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used 6-Hydroxydopamine hydrobromide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Works well.
By Anonymous on 06/15/2020
Assay Type: In Vivo
Species: Mouse
Cell Line/Tissue: neuron

3-4 mg/ml

PMID: 31340159
review image

Great neurotoxic effects in dopaminergic neurons.
By Luiz Alexandre Magno on 07/03/2018
Assay Type: In Vivo
Species: Mouse

I used the 6-Hydroxydopamine (6-OHDA) to deplete dopaminergic cells from the mouse brain, which is largely used as an experimental model of Parkinson's Disease. The 6-OHDA was injected into the mouse striatum and 21 days later we observed that the dopaminergic neurons (positive for tyrosine hydroxylase immunofluorescence) were almost absent in the substantia nigra pars compacta (SNc) from the 6-OHDA injected hemisphere (on the left). As a control for analytical comparisons, we also injected PBS into the contralateral hemisphere (on the right). When this neurotoxin is injected into striatum, as in this case, there is only a slight depletion of dopaminergic neurons from the ventral tegmental area (the region located into the middle of the image). The animals injected with 6-OHDA display several motor dysfunctions and are used to study the pathology and therapies for Parkinsonian symptoms.

Although 6-Hydroxydopamine hydrobromide (6-OHDA.HBr #2547) dissolves very well in aqueous solutions, some tips are necessary to guarantee its stability for biological experiments. 1. When calculating the 6-OHDA concentration, take in consideration that the doses that are often reported are for the free base and not for the hydrobromide (HBr) conjugated salt. Thus, in the case of 6-OHDA.HBr (#2547), the presence of HBr has to be taken into account in making the proper solution. HBr has a molecular weight of 80.91 and represents 32.352% of the 6-OHDA.HBr (#2547) molecular mass.2. Always dissolve the 6-OHDA salt in buffers containing antioxidant capacity. I suggest adding 1 mM ascorbic acid (#4055) into PBS. I know some colleagues that have used sodium metabisulfite as well with great success.3. Always make fresh solutions. The 6-OHDA solution is extremely prone to oxidation, even when resuspended in antioxidant buffers. When fresh, it looks dark red. However, it turns to brown after a few hours.4. Finally, 6-OHDA is extremely toxic. Therefore always be cautious when handling it.

Reference
review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Dopamine Receptors

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.